Reed Jobs would rather talk about curing cancer than his last name
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs's words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.
The latest reports regarding "Reed Jobs would rather talk about curing cancer than his last name" indicate a significant shift in the current situation. Experts are closely monitoring the developments as more data becomes available from official sources. This story is still developing and impact assessments are underway.
Observers suggest that this event could have long-term implications for the tech sector. Stay tuned as we bring you further updates and exclusive footage regarding these recent changes. Our team is working to verify additional details from the ground.
- Warhawk US Senator Lindsey Graham dies
- Ghana slavery apology: Why many descendants say words are not enough
- Sheikh Hamad bin Khalifa Al Thani, architect of modern Qatar
- Live Update: How Aldi is taking on US supermarkets with its $4 almond butter
- Live Update: Will Trump Accounts deliver for American children?
- Live Update: Meta pulls new AI image feature after days of backlash
- Live Update: Will Trump Accounts deliver for American children?
No comments:
Post a Comment